{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T10:40:55Z","timestamp":1788864055240,"version":"build-2803163510"},"reference-count":51,"publisher":"Informa UK Limited","issue":"1","license":[{"start":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T00:00:00Z","timestamp":1771804800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Journal of Medical Economics"],"published-print":{"date-parts":[[2026,12,31]]},"DOI":"10.1080\/13696998.2026.2633930","type":"journal-article","created":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T14:59:34Z","timestamp":1772722774000},"page":"594-608","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":2,"title":["Economic evaluation of perioperative pembrolizumab plus standard of care as treatment for resectable locally advanced head and neck squamous cell carcinoma in the United States"],"prefix":"10.1080","volume":"29","author":[{"given":"Feng","family":"Qian","sequence":"first","affiliation":[{"name":"Merck & Co., Inc","place":["Rahway, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1967-2045","authenticated-orcid":false,"given":"Arielle G.","family":"Bensimon","sequence":"additional","affiliation":[{"name":"Analysis Group, Inc","place":["Boston, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anjela","family":"Tzontcheva","sequence":"additional","affiliation":[{"name":"Merck & Co., Inc","place":["Rahway, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimberly","family":"Benjamin","sequence":"additional","affiliation":[{"name":"Merck & Co., Inc","place":["Rahway, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ravindra","family":"Uppaluri","sequence":"additional","affiliation":[{"name":"Brigham and Women\u2019s Hospital and Harvard Medical School","place":["Boston, USA"]},{"name":"Dana-Farber Cancer Institute","place":["Boston, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas","family":"Adkins","sequence":"additional","affiliation":[{"name":"Washington University in St. Louis","place":["St. Louis, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geoffrey","family":"Johnson","sequence":"additional","affiliation":[{"name":"Merck & Co., Inc","place":["Rahway, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Fernan","sequence":"additional","affiliation":[{"name":"Analysis Group, Inc","place":["Boston, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dandan","family":"Zheng","sequence":"additional","affiliation":[{"name":"Merck & Co., Inc","place":["Rahway, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuexin","family":"Tang","sequence":"additional","affiliation":[{"name":"Merck & Co., Inc","place":["Rahway, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Biruk","family":"Chafamo","sequence":"additional","affiliation":[{"name":"Analysis Group, Inc","place":["Boston, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominic","family":"Muston","sequence":"additional","affiliation":[{"name":"Merck & Co., Inc","place":["Rahway, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2026,2,23]]},"reference":[{"key":"e_1_3_5_2_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-031-50675-8_17"},{"key":"e_1_3_5_3_1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21834"},{"key":"e_1_3_5_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2007.04.002"},{"key":"e_1_3_5_5_1","unstructured":"NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) for Head and Neck Cancers V.5.2025. \u00a9 National Comprehensive Cancer Network Inc. 2025. To view the most recent and complete version of the guideline [accessed 2025 Sep 3]. Available from: NCCN.org."},{"key":"e_1_3_5_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2015.12.017"},{"key":"e_1_3_5_7_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa032641"},{"key":"e_1_3_5_8_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa032646"},{"key":"e_1_3_5_9_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2022-069047"},{"key":"e_1_3_5_10_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6602510"},{"key":"e_1_3_5_11_1","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.5815"},{"key":"e_1_3_5_12_1","doi-asserted-by":"publisher","DOI":"10.1186\/s41199-020-00052-8"},{"key":"e_1_3_5_13_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2415434"},{"key":"e_1_3_5_14_1","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2020-0595"},{"key":"e_1_3_5_15_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-46444-z"},{"key":"e_1_3_5_16_1","unstructured":"U.S. Food & Drug Administration. FDA approves neoadjuvant and adjuvant pembrolizumab for resectable locally advanced head and neck squamous cell carcinoma. 2025. Available from: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-neoadjuvant-and-adjuvant-pembrolizumab-resectable-locally-advanced-head-and-neck"},{"key":"e_1_3_5_17_1","doi-asserted-by":"publisher","DOI":"10.1177\/0272989X16651869"},{"key":"e_1_3_5_18_1","doi-asserted-by":"publisher","DOI":"10.1177\/0272989X16670617"},{"key":"e_1_3_5_19_1","unstructured":"National Institute for Health and Care Excellence. DSU technical support document 19: partitioned survival analysis for decision modelling in health care: a critical review. 2017."},{"key":"e_1_3_5_20_1","doi-asserted-by":"publisher","DOI":"10.1002\/sim.2712"},{"issue":"12","key":"e_1_3_5_21_1","first-page":"1","article-title":"United States life tables","volume":"72","author":"Arias E","year":"2023","unstructured":"Arias E, Xu J, Kochanek K. United States life tables. Natl Vital Stat Rep. 2023;72(12):1\u201364.","journal-title":"Natl Vital Stat Rep"},{"key":"e_1_3_5_22_1","unstructured":"National Institute for Health and Care Excellence. DSU Technical Support Document 14: survival analysis for economic evaluations alongside clinical trials - extrapolation with patient-level data. 2013. Available from: http:\/\/nicedsu.org.uk\/wp-content\/uploads\/2016\/03\/NICE-DSU-TSD-Survival-analysis.updated-March-2013.v2.pdf"},{"key":"e_1_3_5_23_1","unstructured":"Centers for Medicare & Medicaid Services. 2025. Physician fee schedule. Available from https:\/\/www.cms.gov\/medicare\/physician-fee-schedule\/search"},{"key":"e_1_3_5_24_1","doi-asserted-by":"publisher","DOI":"10.1002\/lary.22447"},{"key":"e_1_3_5_25_1","doi-asserted-by":"publisher","DOI":"10.1002\/lary.21348"},{"key":"e_1_3_5_26_1","doi-asserted-by":"publisher","DOI":"10.1002\/lary.22409"},{"key":"e_1_3_5_27_1","doi-asserted-by":"publisher","DOI":"10.1002\/lary.23952"},{"key":"e_1_3_5_28_1","unstructured":"Centers for Medicare & Medicaid Services. 2025. Hospital outpatient prospective payment system. Available from: https:\/\/www.cms.gov\/medicare\/payment\/prospective-payment-systems\/hospital-outpatient"},{"key":"e_1_3_5_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2018.04.018"},{"key":"e_1_3_5_30_1","volume-title":"HCUP Nationwide Inpatient Sample","author":"Healthcare Cost and Utilization Project","year":"2021","unstructured":"Healthcare Cost and Utilization Project. HCUP Nationwide Inpatient Sample; 2021. Rockville (MD): Agency for Healthcare Research and Quality."},{"key":"e_1_3_5_31_1","unstructured":"Nash Smyth E La E Talbird S et al. Treatment patterns and healthcare resource use (HCRU) associated with repeatedly treated metastatic squamous cell carcinoma of the head and neck (mSCCHN) in the United Kingdom (UK). Poster presented at ISPOR 18th Annual European Congress Milan Italy Nov 2015. Available from: https:\/\/www.rtihs.org\/sites\/default\/files\/26242%20Kaye%202015%20Treatment%20patterns%20and%20health%20care%20resource%20use%20%28HCRU%29%20associated%20with%20repeatedly%20treated%20metastatic%20squamous%20cell%20carcinoma.pdf?_gl=1*ir04s7*_up*MQ.*_ga*NjU3Njc2NjYuMTczMDg0Njc2Mw.*_ga_SV53VWG53G*MTczMDg0Njc2MS4xLjAuMTczMDg0Njc2MS4wLjAuMA.*_ga_T5ND07SFL4*MTczMDg0Njc2MS4xLjAuMTczMDg0Njc2MS4wLjAuMA"},{"key":"e_1_3_5_32_1","unstructured":"National institute for Health and Care Excellence. Nivolumab for treating recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy [TA736 formerly TA490]. 2021. Available from: https:\/\/www.nice.org.uk\/guidance\/ta736"},{"key":"e_1_3_5_33_1","doi-asserted-by":"publisher","DOI":"10.1080\/13696998.2022.2095826"},{"key":"e_1_3_5_34_1","unstructured":"Centers for Medicare & Medicaid Services. 2025. Clinical laboratory fee schedule. Available from: https:\/\/www.cms.gov\/medicare\/payment\/fee-schedules\/clinical-laboratory-fee-schedule-clfs"},{"key":"e_1_3_5_35_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoto.2015.2162"},{"key":"e_1_3_5_36_1","unstructured":"Bureau of Economic Analysis. Table 2.3.4. Price indexes for personal consumption expenditures by major type of product. Available from: https:\/\/apps.bea.gov\/iTable\/?reqid=19&step=2&isuri=1&categories=survey&_gl=1*4if4xa*_ga*MTU1OTczMjYyNy4xNzM5OTAzNjEy*_ga_J4698JNNFT*MTczOTkwMzYxMS4xLjEuMTczOTkwNTQzMi4yMC4wLjA.#eyJhcHBpZCI6MTksInN0ZXBzIjpbMSwyLDMsM10sImRhdGEiOltbImNhdGVnb3JpZXMiLCJTdXJ2ZXkiXSxbIk5JUEFfVGFibGVfTGlzdCIsIjY0Il0sWyJGaXJzdF9ZZWFyIiwiMjAwNiJdLFsiTGFzdF9ZZWFyIiwiMjAyNCJdLFsiU2NhbGUiLCIwIl0sWyJTZXJpZXMiLCJBIl1dfQ=="},{"key":"e_1_3_5_37_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2017.0973"},{"key":"e_1_3_5_38_1","doi-asserted-by":"publisher","DOI":"10.1002\/hed.26793"},{"key":"e_1_3_5_39_1","doi-asserted-by":"publisher","DOI":"10.17305\/bb.2023.8978"},{"key":"e_1_3_5_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2017.07.054"},{"key":"e_1_3_5_41_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12913-021-07149-x"},{"key":"e_1_3_5_42_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2015.11.006"},{"key":"e_1_3_5_43_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2016.11.029"},{"key":"e_1_3_5_44_1","doi-asserted-by":"publisher","DOI":"10.1080\/13696998.2025.2510807"},{"key":"e_1_3_5_45_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.oraloncology.2018.10.032"},{"key":"e_1_3_5_46_1","doi-asserted-by":"publisher","DOI":"10.1080\/13696998.2020.1715414"},{"key":"e_1_3_5_47_1","unstructured":"National Institute for Health and Care Excellence. Pembrolizumab with chemotherapy before surgery (neoadjuvant) then alone after surgery (adjuvant) for treating resectable non-small-cell lung cancer [TA1017]. 2024. Available from: https:\/\/www.nice.org.uk\/guidance\/ta1017"},{"key":"e_1_3_5_48_1","unstructured":"Canada\u2019s Drug Agency-L\u2019Agence des m\u00e9dicaments du Canada (CDA-AMC). Reimbursement review: pembrolizumab (Keytruda) for non-small cell lung cancer neoadjuvant [project number: PC0385]. 2025. Available from: https:\/\/www.cda-amc.ca\/sites\/default\/files\/DRR\/2025\/PC0385-Keytruda_Combined_Review.pdf"},{"key":"e_1_3_5_49_1","unstructured":"National Institute for Health and Care Excellence. NICE health technology evaluations: the manual [PMG36]. 2022. Available from: https:\/\/www.nice.org.uk\/process\/pmg36\/chapter\/introduction-to-health-technology-evaluation."},{"key":"e_1_3_5_50_1","unstructured":"Canada\u2019s Drug Agency-L\u2019Agence des m\u00e9dicaments du Canada (CDA-AMC). Guidelines for the economic evaluation of health technologies: Canada. 4th ed. Ottawa. 2017. Available from: https:\/\/cadth.ca\/sites\/default\/files\/pdf\/guidelines_for_the_economic_evaluation_of_health_technologies_canada_4th_ed.pdf"},{"key":"e_1_3_5_51_1","volume-title":"Decision modelling for health economic evaluation","author":"Briggs A","year":"2011","unstructured":"Briggs A, Claxton K, Sculpher M. Decision modelling for health economic evaluation. New York (NY): Oxford University Press; 2011."},{"key":"e_1_3_5_52_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.02625"}],"container-title":["Journal of Medical Economics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/13696998.2026.2633930","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T14:59:37Z","timestamp":1772722777000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/13696998.2026.2633930"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,23]]},"references-count":51,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,12,31]]}},"alternative-id":["10.1080\/13696998.2026.2633930"],"URL":"https:\/\/doi.org\/10.1080\/13696998.2026.2633930","relation":{},"ISSN":["1369-6998","1941-837X"],"issn-type":[{"value":"1369-6998","type":"print"},{"value":"1941-837X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,23]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ijme20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ijme20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2025-12-25","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-02-14","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-02-16","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-02-23","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}